Peloton Introduces Its First-Ever Health And Wellness Advisory Council – PRNewswire

Posted on by

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Peloton (NASDAQ: PTON), the world's largest interactive fitness platform, today announced the formation of the Peloton Health and Wellness Advisory Council, which will work closely with the company as it continues to look at how it can positively impact the physical, mental and emotional wellbeing of its community of Members from around the world. Peloton will collaborate with the council, which includes five renowned doctors, researchers and other medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience, and draw on their knowledge and expertise to help inform product and content development, community-focused and social impact initiatives, research projects and more.

"We constantly hear from our Members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression," said William Lynch, president, Peloton. "With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform."

The Peloton Health and Wellness Advisory Council includes the following experts:

Cardiovascular MedicineSuzanne Steinbaum, MD:Dr. Suzanne Steinbaum is an attending cardiologist, specializing in prevention. She has recently opened a private practice in New York City, at the Juhi-Ash integrative health center encompassing heart health, wellness and prevention, as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a personalized lifestyle management program using anatomy, physiology, functional data, genetics and metabolism, along with technology to reach ultimate cardiovascular health. She has been the Director of Women's Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Women's Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Women's Heart Alliance.

NeurologyRichard S. Isaacson, MD:Richard S. Isaacson, M.D. is a Neurologist, clinician and researcher who specializes in Alzheimer's prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimer's disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimer's Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimer's disease, Journal of Communication in Healthcare, Alzheimer's & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Vernon Williams, MD:Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, CA. Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commission's Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty: Sports Neurology and Pain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Cardiopulmonary ExerciseAimee M. Layton, PhD:Aimee Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center / New York Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being director of the adult pulmonary exercise laboratory for a decade. This cross discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Layton's prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids' behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

NeuroscienceJay Alberts, PhD:As a Cleveland Clinic Scientist, Ph.D., Jay Alberts' research is aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinson's disease, stroke, Alzheimer's and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinson's disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer reviewed articles, has had uninterrupted extramural funding since 1999 and holds 10 patents.

For more information about Peloton or the Peloton Health and Wellness Advisory Council, please visit http://www.blog.onepeloton.com.

About PelotonPeloton is the largest interactive fitness platform in the world with a loyal community of more than 2.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. Peloton makes fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage its Members to be the best versions of themselves. An innovator at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry by developing a first-of-its-kind subscription platform that seamlessly combines the best equipment, proprietary networked software, and world-class streaming digital fitness and wellness content, creating a product that its Members love. The brand's immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which allows access to a full slate of fitness classes across disciplines, on any iOS or Android device, Apple TV, Fire TV, Roku TVs, and Chromecast and Android TV. Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit http://www.onepeloton.com.

SOURCE Peloton

http://www.pelotoncycle.com

Go here to read the rest:
Peloton Introduces Its First-Ever Health And Wellness Advisory Council - PRNewswire

This COVID-19 Practice: The Pandemic Wreaks Havoc on… : Neurology Today – LWW Journals

Posted on by

Article In Brief

The loss of revenue to institutions and philanthropies due to COVID-19 has taken a toll on the neurology research enterprise. The exceptionstudies related to the novel coronavirus.

Furloughed technical staff. Cancelled fundraising walks. Paused grant reviews. Busted budgets.

In myriad ways, the financial foundations of neurology research have been undermined in just the first few months of the COVID-19 pandemic and may well grow worse in the months to come, according to academic neurologists and officials at the charitable organizations that fund their studies.

For sure, new opportunities for research funds related to COVID-19 are making up some of the difference. But doubts remain that they could cover all the losses.

Every passing month, it gets harder and harder, said Brett Kissela, MD, MS, FAAN, the Albert Barnes Voorheis Professor and Chair of the department of neurology and rehabilitation medicine at the University of Cincinnati College of Medicine. Our business people are looking at the books and seeing we've lost a huge amount of research-related revenue.

As senior associate dean for clinical research, Dr. Kissela has had a bird's eye view on how COVID-19 has affected all categories of medical research.

Some critical research, like cancer trials, we kept open, but otherwise we really had to shut down the non-COVID research enterprise, he told Neurology Today. We're still accruing expenses but not able to generate revenues. It's a huge financial hit.

One major source of research funding, he said, comes from pharmaceutical companies, which typically pay medical schools per patient enrolled in a given trial.

Some of the companies have really been hoping we can get started again, Dr. Kissela said. The longer a study goes, the more it costs them. We'd all like to re-start. But we can only go slowly. We don't want to put patients or staff at risk, and definitely don't want to become a hot spot.

Another major source of study funding, from charitable organizations, has also been hit hard by the pandemic.

It's had a big impact, said Howard Fillitt, MD, founding director and chief science officer of the Alzheimer's Drug Discovery Foundation. Across the board, in talking with our colleagues at other non-profits, we've heard that fundraising is down this year. It's a very difficult situation.

On the bright side, a spate of new funding opportunities has opened for studies looking at the neurologic component of COVID-19. But with labs forced to practice social distancing and patients reluctant to enter hospitals, even those studies may prove difficult for neurologists to implement.

So far at the University of Cincinnati, there have been no furloughs or work reductions for research staff, Dr. Kissela said.

The problem is, if you're too aggressive with furloughs or pay cuts, you could lose valuable people for when you're finally ready to get back to full employment, he said. We're beginning a cautious return to research now, and hoping we'll be able to return to full speed sometime soon.

The biggest impact has been on technical staff who cannot do their work from home, said D. James Surmeier, PhD, the Nathan Smith Davis Professor and Chair of Physiology at the Feinberg School of Medicine at Northwestern University.

The postdoctoral fellows and grad students are more flexible, said Dr. Surmeier, who researches the mechanisms underlying Parkinson's disease, Huntington's disease and chronic pain. But there's really very little the technical staff can do from home. They're not in the position to analyze data or write manuscripts. Their primary job function is to maintain animal colonies, do genotyping, to be in the lab where the equipment is.

Some staffers have children, whose schools have been closed, and so the staffers cannot come into the office. Even for those who can come in, the continuing need for social distancing is forcing Dr. Surmeier to establish shifts to maintain safety. That means studies must proceed more slowly.

Some funding agencies, like NIH, are being very understanding about the need for extended deadlines, Dr. Surmeier said. But some of our private funders have more limited resources. I completely understand their position: They have a limited amount of money to accomplish their goals. The result is that we are having to furlough some people. The staff can't work, and the funder has refused to pay for idle time.

Even with the no-cost extensions offered by NIH, he added, There is a continuing cost that we simply can't turn on and off at will. I'm afraid that we will be forced to significantly down-size our scientific infrastructure if the situation does not change soon.

Deborah A. Hall, MD, PhD, FAAN, the Parkinson's Foundation professor of neurological sciences and head of the movement disorders section at Rush University Medical Center, said she has not had to lay off any of her 13 research staffers yet, even though most have been forced to work from home.

We've spent a lot of extra time writing requests for grant extensions and deadline postponements, she said. Although clinics at Rush re-opened on May 11, she said, non-essential research activities had not been scheduled to resume until June 1.

We will have to stagger the schedules of research staff to keep them socially distanced, Dr. Hall said. My group has 115 active studies underway. We will have to make decisions about which studies open initially and which ones stay on pause.

The Alzheimer's Drug Discovery Foundation made grants totaling approximately $30 million last year, said Dr. Fillit. This year, he said, I don't want to be too negative. Our fundraising is in good shape. There's a lot of optimism that facilities will be re-opening. The research will go on.

Officials at other charitable organizations were not quite so rosy.

We're talking with our grantees about adjusting the scope of their programs where feasible and re-budgeting the needs they might have, said Heather Snyder, PhD, vice president of medical and scientific operations for the Alzheimer's Association. We know dementia is not stopping. We are working closely with our senior leadership and advisors to look at potential ways we can support particular projects, including where some might have increased costs.

Mark Frasier, PhD, senior vice president of research programs at the Michael J. Fox for Parkinson's Research (MJFF), said that the organization has no endowment, and spends essentially everything it brings in via donations. Last year, that amounted to over $100 million in grants, a record for the foundation.

In terms of new grant-making, we are seeing some adjustments, he said. There have obviously been cancellations of fundraising events.

One of the biggest, the Parkinson's Unity Walk in New York City's Central Park, had been scheduled for April 25, raised over $1.5 million last year. (The event benefits a number of PD organizations, including MJFF.) Many other events, scheduled as part of Parkinson's Awareness Month in April, were likewise cancelled.

We have not paused grant-making entirely, Dr. Frasier said. We are continuing to make grants, although we are being more careful and scrutinizing them to be sure they are of the utmost priority. The good news is that our fundraising, like that of most non-profits, is year-end heavy. Charitable giving increases around the holidays. Most of our fundraising occurs from October to December. We feel like that is a good thing. We may get closer to a recovery toward the end of the year.

Jennifer Bain, MD, PhD, assistant professor of neurology at Columbia University Irving Medical Center, said she is seeing a shift in the kinds of research opportunities being offered by funding agencies.

Previously funded research is continuing, but new research seems to be shifting toward COVID-19, said Dr. Bain, who specializes in the study of rare neurodegenerative developmental disorders. The Autism Science Foundation, for instance, is offering new pivot grants to help scientists facing hardship due to the COVID-19 emergency. It's been interesting to see the shift toward funding for how to transition your research in the world of COVID.

In April, for example, the National Institute of Neurological Disorders and Stroke announced it was seeking research on the biological effects of COVID-19 on the central nervous system; grant applications not to exceed $200,000 in direct costs, must be submitted by April 15, 2021.

Also, in April, the National Institute on Aging announced grants for research on improving the prevention of disease transmission among older adults and mitigation of disease severity and mortality in older adults with the virus. Applications are open until May 1, 2021.

Dozens of other COVID-related funding opportunities from the National Science Foundation, the US Department of Defense, the Centers for Disease Control and Prevention, NIH, the US Department of Health and Human Services, and other sources have been listed on a webpage of the University of Michigan

Read more:
This COVID-19 Practice: The Pandemic Wreaks Havoc on... : Neurology Today - LWW Journals

What to expect when getting Alzheimer’s or dementia diagnosis – sidneydailynews.com

Posted on by

DAYTON Currently, there is no single test that can show whether a person has Alzheimers disease, although researchers are getting closer to having an available blood biomarker.

Today diagnosing Alzheimers requires careful medical evaluation, including:

A thorough medical history

Mental status testing

A physical and neurological exam

Tests (such as blood tests and brain imaging) to rule out other causes of dementia-like symptoms.

There is great benefit to getting an early diagnosis. While there is not a cure for Alzheimers disease, medications may reduce symptoms or provide cognitive clarity for some.

Getting a medical workup

During the medical workup, your health care provider will review your medical history. He or she will want to know about any current and past illnesses, as well as any medications you are taking. The doctor will also ask about key medical conditions affecting other family members, including whether they may have had Alzheimers disease or related dementias.

Mental status testing

This part evaluates memory, ability to solve simple problems and other thinking skills. Such tests give an overall sense of whether a person is aware of symptoms, knows where he or she is, and can remember a short list of words or follow instructions. The mini-mental state exam and mini-cog test are two commonly used tests.

Neurological exam

During a neurological exam, the physician will closely evaluate the person for problems that may signal brain disorders other than Alzheimers. The doctor will look for signs of small or large strokes, Parkinsons disease, brain tumors, fluid accumulation on the brain, and other illnesses that may impair memory or thinking.

Continue reading here:
What to expect when getting Alzheimer's or dementia diagnosis - sidneydailynews.com

New Research Finds Troubling Link Between COVID-19 and Neuropsychiatric Health – Psychiatric Times

Posted on by

From the beginning of the COVID-19 outbreak, clinicians have known that the virus can cause acute respiratory distress. Anew study suggests it may have neuropsychiatric effects as well.

That is according to a team of British scientists, who recently published a paper on neuropsychiatric complications stemming from COVID-19. In an online edition of The Lancet, the researchers reported an array of symptoms, from strokes to altered mental states like new-onset psychosis.1 Surprisingly, they discovered that acute alterations in mental status were disproportionately overrepresented in younger patients.

Up until now, published reports on COVID-19s neuropsychiatric effects have been largely anecdotal, limited to individual cases or a small case series. The British study is the first nationwide survey, which was based on 153 cases submitted by clinicians across the United Kingdom. It was undertaken to explore the proportion of neurological and psychiatric complications that affect the central nervous system versus the peripheral nervous system, as well as who was most at risk for these symptoms.

The researchers found a number of psychiatric complications. Altered mental status was the second most common presentation, they wrote. Of patients with complete datasets, 31% received a psychiatric diagnosis. Clinicians reported 4 cases of affective disorders, 6 cases of dementia-like symptoms, and 10 cases of new-onset psychosis. There was also 1 case of catatonia and another of mania. Only 2 patients had exacerbations of existing enduring mental illness.

According to the reports authors, altered mental states are common in cases of severe infection, but this symptom typically predominates in older groups.The COVID-19 data told a different story. Almost half of the patients with psychiatric complications from COVID-19 were 59 years or younger.

The authors offered at least 1 possible explanation. The large number of patients with altered mental status might reflect increased access to neuropsychiatry or psychiatry review for young patients, they wrote. But the exact relationship between COVID-19 and mental health remains a mystery, especially where younger individuals are concerned. The authors insist that confirmation of the link between COVID-19 and new acute psychiatric or neuropsychiatric complications in younger patients will require detailed prospective longitudinal studies.

Although further study may be necessary to draw firm conclusions, one thing is certain: Severe neurological and neuropsychiatric presentations associated with COVID-19 have become increasingly apparent.

Reference

1. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study [published online ahead of print, 2020 Jun 25] [published correction appears in Lancet Psychiatry. 2020 Jul 14;:]. Lancet Psychiatry. 2020; S2215-0366(20)30287-X.

Link:
New Research Finds Troubling Link Between COVID-19 and Neuropsychiatric Health - Psychiatric Times

Dr. Edward Aulisi: The QB of the OR Heads a Neurological Surgical Team Which Performed a Groundbreaking Procedure – TAPinto.net

Posted on by

Forty years ago, Edy Aulisi was wearing the Blue and Gold of Belleville High, playing quarterback for the football team, guard on the basketball squad and as a standout pitcher on the baseball team.

In addition to being a stalwart athlete, Aulisi also excelled in the classroom, so much so that he was the valedictorian for Belleville High's Class of 1980.

The son of Mildred and the late Joseph Aulisi, Edy grew up with four older sisters,Donna, Annie, Flora and Barbara and a younger sister, Lisa.

Sign Up for Bloomfield Newsletter

Our newsletter delivers the local news that you can trust.

You have successfully signed up for the TAPinto Bloomfield Newsletter.

He would take that extraordinary talent as a student-athlete, to Princeton University, where he began his quest to become a neurosurgeon while playing four years of baseball, including being a team captain in 1984, and two seasons on the football team.

After graduating from Princeton, in 1984, Aulisi would go on to medical school at George Washington University, in Washington, DC.

Four decades removed from his days at Belleville High, Dr. Edward Aulisi is a renown neurologist, serving as Chairman of Neurosurgery at MedStar Washington Hospital Center, in downtown Washington, DC.A husband and father of three,Aulisiand his medical team made history on June 10, 2020, performing the first spinal surgery, in the nation, usingBrainlab'sCirqRobotics.

"It's exciting technology, and I'mproud to be chosen as the first neurosurgeon to try it out," said Aulisi.

And in true Belleville High football lingo, he followed that up by saying, "Keep moving the ball forward!"

The procedure was centered around a surgeon-controlled robotic arm, designed to increase precision and accuracy, while speeding the recovery process for patients who undergo spine surgery.

"It was really something," said Aulisi. "The patient knew she was going to be the first to undergo this surgery, and she was excited about it. We were able to perform a Cat Scan (or CT Scan) when the wound is still open. The recovery process is also faster, and the accuracy of the robot, when it comes to spinal surgery, which is so important, is incredible."

Aulisi went on to perform the same surgery on other patients, on June 11 and 12, as well as into the following week.

In the long-running Broadway show, 'Jersey Boys', one of the first lines is 'It all started in Belleville, NJ.' And for Aulisi, that was so true. He was a star quarterback for the Belleville Bellboys in 1977 and continued that as a Buccaneer in 1978 and 1979.

"(Assistant coach) Joe D'Ambola was handing out jerseys (in '77)," recalled Aulisi. "When he saw me, he tossed jersey number 12 at me and said I looked like Joe Willie (Namath)."

Aulisi would guide the '77 Bucs, as a sophomore, after earning the starting quarterback job five games into the season.

"(Belleville head coach) John Senesky had the foresight to run the Delaware Wing T," said Aulisi. "He was so far ahead, when it came to preparation. He was an amazing coach."

Auilsi also spoke with pride of all the assistants on the staff during his time at BHS, and what they meant to him.

"Bill Bakka was my freshman coach," he said., (More to come on that later).Carl Carino used to put the pads and helmet on and scrimmage with us, Coach Mike Welsh was a man of few words. (William) 'Doc' Ellis always said to me, 'Edy, just relax, youve got this'. Carl Papaianni was always relaxed and confident. He knew my dad when he was younger, but never gave me an inch of favoritism.

"Ralph Borgess Jr. was legendary. He had us so amped up for our first game, in my senior year. We were all crying when we came out on the field. Coach Vitiello always said to meEdy point your toe where you want to throw, and I used that advice all through college. Great memories from all those guys."

He recalls his third start at quarterback, in 1977. The Bellboys were host to the Pony Pirates of Seton Hall Prep, a marvelous football team, which came into the game with a 5-0-1 record.

"My two cousins, Joe and Ed, were on that Seton Hall team," said Aulisi. "Anyway, it wasn't going very well. Seton Hall was up 42-0 at halftime and actually took their foot off the pedal in the second half, and we lost, 63-0. My cousin Joe sacked me on one play and he kind of lifted me up afterward."

Those '77 Bellboys were a young group. Many had found early success as a member of the Belleville Broncos youth team. But once in high school, with a new coach, it took time to develop. The '77 Bellboys finished 2-6-1 and the following year, the team, in its first season known as the Buccaneers, improved to 6-3.

"We worked hard in the off-season, got stronger and by our senior year, we were pretty good," said Edy.

Two years, nearly to the day, after the 63-0 loss, Seton Hall Prep would return to Municipal Stadium. This time, the Buccaneers would win, 14-13, when Aulisi threw a touchdown pass to Lenny Mendola in the game's closing minute, and Ralph DiPasquale kicked the point-after to secure a memorable game.

"Probably the biggest win of my high school career," said Aulisi. "I remember throwing a touchdown pass earlier in the game to Jerry DiGori, and then Lenny made a great move to the end zone and I was able to hit him with the winning touchdown pass.

"Two years earlier, Seton Hall had manhandled us, and they had a pretty good team in '79, too. It meant a lot to win that game."

The 1979 Buccaneers would finish 8-2 and earn the program's first-ever playoff berth. On Nov. 17, it played Union High, at Giants Stadium, and lost a heart breaker 15-12.

"Playing at Giants Stadium was really something special," said Aulisi.

Aulisi also spoke with fondness of his other high school coaches.

"Danny Grasso, my basketball coach, is a really good man. He started working with us at a young age, and really took the time to help us learn the game. I remember he always dressed real well for the games. And my baseball coach,, George Zanfini was someone really special. There's nothing any of us wouldn't have done for him."

Edy also praised his teachers at Belleville High, most notably Angie DiMaggio, the long-time history teacher at the school.

"I remember once when I wrote a paper, and I thought it was pretty good," said Aulisi. "And Mrs. DiMaggio said to me, 'you can do better, Edy. ,You're going to Princeton next year. Believe me, you can do better.' That really meant something. And she was right, too."

Aulisi's ascent to Princeton University was certainly challenging.

"I was a good student in high school, a valedictorian and then I get to Princeton and I'm taking some really tough classes, like organic chemistry and other neuroscience classes. I'm also playing on the football team (in the fall) and the baseball team (spring time) as well as competing in the classroom with other students, many of whom were also valedictorians of their class. It was a big step."

MedStar Washington Hospital Center, in Washington, where Aulisi works, is just a three mile drive from the Smithsonian Institute. Thereanother Belleville High success story,LonnieBunch, is Secretary of the Smithsonian. In his position, Bunch oversees 19 museums, 21 libraries and the National Zoo, as well as numerous research centers and several education units and centers.Bunch was graduated from Belleville, in 1970, 10 years beforeEdy

"Lonnie's career has been incredible," said Edy. "Think about what he's done to get to where he is today. I'm so happy for him."

While Aulisi resides outside of Washington, his Belleville roots remain strong. He speaks fondly of his days at School #5, where Mike Nicosia and Lenny Mendola were among his classmates and future teammates on the football team.

And having grown up in a large family, it's easy to say that Aulisi takes tremendous pride in his own family. He and his wife, Gabriele have three children, son Joseph (25) and twins Ariana and Domenic, 21.

An interesting story, with a Belleville twist. In 2008, Aulisi was on call in a Washington DC emergency room when a young woman was rushed in, unresponsive. Aulisi would diagnose the patient and then had her transported to Georgetown University for further analysis.

Unbeknownst to him at the time, it turned out the woman was the daughter of Edy's freshman football coach, at Belleville, Bill Bakka who Edy hadn't seen in at least 30 years.

Aulisi's quick thinking on Bill's daughter's condition ultimately saved her life.

When it comes to his work, Aulisi's primary concern is that of his patient. He also, like a true quarterback, praised his teammates, in this case a very talented medical staff .

"My team works so hard," said Aulisi. "I guess you can call me the quarterback of the operating room, but I work with some great people. For my entire career, it's always been about the patient. What's best for the patient is what's best for Ed Aulisi."

More here:
Dr. Edward Aulisi: The QB of the OR Heads a Neurological Surgical Team Which Performed a Groundbreaking Procedure - TAPinto.net

An Alzheimer’s Disease Researcher and Master Sculptor… : Neurology Today – LWW Journals

Posted on by

An iron worker inspired this Alzheimer's disease researcher to develop his craft of wood and metal sculptures, which often reflect brain themes. Outside of his research, he teaches art and art history.

There is a story that Peter Snyder, PhD, likes to tell about going home to rummage through his childhood closest. There, he found an original 16-millimeter film of Jose Manuel Rodrguez Delgado's famous Bull Fight experiments under a pile of pajamas. Snyder's father, Daniel, was a neuroscientist and did a fellowship under Delgado, a pioneer in electrical brain stimulation at Yale University, back in the late 1960s.

Peter Snyder grew up in his father's laboratories, befriending macaques, falling into step in their social hierarchy. It was the natural flow of things that he followed his father into neuroscience. But the young Snyder also inherited some impressive artistic skills from his grandmothers, and pretty much split his time between science and art at Boston University and then University of Michigan, where he joined the Potters Guild. (His maternal grandmother, Sylvia, worked with stone and wood. His other grandmother, Belle, was a painter.)

While Snyder continued his graduate studies at Michigan State and would spend the first decade of his career as a neuropsychologist working with epilepsy patients, and then Alzheimer's patients, it was the celebration of his 40th birthday that made him rekindle his passion for art and design. By then, he was a ceramist of noteat least in his living roombut he had been dabbling and tinkering with wood and metal and became interested in the lost art of woodturning. He signed on to a course near his home in Connecticut but quickly realized that using a wood lathe and the hand-held toolsthe wood spins very fastwas a recipe for disaster without one-on-one instruction.

Snyder went home after the class and searched online for local woodturners and saw some beautiful pieces in several Massachusetts galleries. He found the artist's number and called. You don't know me but I love your work that I saw on the web, Dr. Snyder said. There was a long pause...long. Quietly, Kenneth Dubay said: What's the web?

Dubay had spent his career as an ironworker who could build anything with his hands, said Dr. Snyder. Born and raised in Northern Maine, Dubay never attended college but became Dr. Snyder's greatest mentor and teacher. Dubay took up woodturning in retirementhe was in his late 60's when they metand if he needed a tool, he'd just build it.

He never had any training as a teacher but he was patient and kind and thoughtful. He would let me make mistakes and then he would gently point out my errors with good humor and correct me, Dr. Snyder said.

Dr. Snyder became a regular in the Dubay household, and for the next seven yearsduring his tenure at University of Connecticut and then at Brown Universityhe would spend a long, delightful day every other week in Dubay's studio (which he built by hand, along with the log house he shared with his wife) and one weekend every month. Dr. Snyder was an apprentice in the best of ways. They would turn in the morning, stop for lunch, and spend the afternoon sanding the pieces.

Ken taught me about my own style as a mentor, he said. He was selfless. When Dubay passed away in 2011, his wife presented his apprentice with many of his handmade tools, including a long, thin gouge that is used to shape the wood as it is spinning. He keeps that gouge, with Dubay's name inscribed on it, in his car to remind him of his teacher.

While Dr. Snyder was teaching and overseeing research at Brown's teaching hospitals, he helped organize an exhibit on medicine and industrial design with The Rhode Island School of Design (RISD). This led to his co-teaching a RISD advanced studio course for six years, focusing on designing homes and products for older people to age-in-place.

His experience with Alzheimer's disease (AD)working on AD drug discovery, cognitive testing instruments, and biomarker development at Pfizer, and then AD research at Brown and now the University of Rhode Island, where he serves as the university's vice president for researchhelped guide the direction for the course.

He continues on as a sculptor. Many of his pieces include Purkinje cells, dendrites, and axons etched into his mediumwood. He can't help but meld his two worlds. He is now working on developing a retinal biomarker for AD and one of his pieces, Quiet, is made with Colorado Alabaster, cold-formed steel, vintage brass chain and beads and Osage Orange wood, turned and carved with pyrography.

The 16 diameter platter underneath the turned alabaster lamp is from live-edge box elder burl, with wood-burning of the superficial retinal vasculature of his right eye, in the region of the optic nerve head. The image was captured using an optical coherence tomography (OCT) scan of his own retina.

As a clinical neuropsychologist and neuroscientist, I have always protected both time and educational opportunities as an artist. I see the domains of visual arts and the sciences as inextricably intertwined, Dr. Snyder explains of his cellular passions.

The visual arts are essential for conveying the complexity, beauty, organizational structures, and fragility of our natural world. Artistic expression affords science a vital means of allowing us all to appreciate the exquisite complexity of scientific data that are difficult to convey by words alone.

Each day I am torn between the beauty and biologic complexity of our brains and eyes, and the suffering that Alzheimer's disease foists on my affected patients, research participants, their caregivers and their families. As an artist, I use my craft to study this tension. I work to create fluid forms in wood and metals that are reminiscent of organic, natural artifactsranging from cell assemblies to organisms to miniature landscapes.

All pieces start with spinning wood on the lathe, but they are then altered in various ways by carving, wood-burning, staining, and the inclusion of stones or metals. His 900-pound lathe, the size of a grand piano, sits at the sculpture studio on the URI campus.

Another piece finished in 2017 is called Purkinje Cell Vessel I and it is made with spalted maple with copper leaf and pyrography and curved ebony legs. Look closely and you will see a Golgi stain motif of a cerebellar Purkinge cell, based on a famous ink drawing by one of Snyder's academic heroes, Santiago Ramn y Cajal.

More recently, he is moving in uncharted artistic territory. His latest piece is on gun violence. A colleague collects decommissioned guns and has been donating them to artists with hopes that they create something to pay respects to those lost by violence. Dr. Snyder obliged, though it wasn't easy. He used ash wood with pyrography, plasticene clay, iron oxide wash and acrylics, and he inscribed it with the names of about 65 children who were killed in school shootings between 2015 and 2018, taking time to reflect on each of their stories. The piece will be part of a touring art exhibit on gun violence, although it has been delayed due to the current national lockdown.

I was unable to get its design out of my mind any other way, and it reflects my anger and disgust at our society's inability to appropriately control the licensing and possession of guns.

Most of the children's names have been covered by the clay, the iron oxide wash and red acrylic paint that Dr. Snyder said represents the toxic, bloody effluent mass being released by the handgun.

Dr. Snyder continues his scientific and artistic works, and mentoring students across these disciplines, in the department of biomedical and pharmaceutical sciences, and in the department of art and art history, at the University of Rhode Island.

See the original post:
An Alzheimer's Disease Researcher and Master Sculptor... : Neurology Today - LWW Journals

SOC Telemed Supports Phelps Health with Round-The-Clock teleNeurology Services – Stockhouse

Posted on by

RESTON, Va., June 9, 2020 /PRNewswire/ -- SOCTelemed (SOC) announced today the successful launch of emergency and inpatient teleNeurology services at Phelps Health, a health system in Rolla, Missouri, serving six counties.

Phelps Health selected SOC's Telemed IQ platform to access emergency neurology care around the clock, on-demand in the emergency department. SOC neurologists will also serve as an on-call teleNeurology support system in the inpatient neurology department, bolstering the hospital system's on-staff neurologists with extra support and flexibility.

"The Telemed IQ platform allows hospitals like Phelps Health to serve their communities with confidence," said Jason Hallock, chief medical officer at SOC Telemed. "In neurology, stroke care, emergency psychiatry, critical care, cardiology and beyond, we connect specialized experts to hospitals in need, seamlessly."

The launch of teleNeurology at Phelps Health is poised to reduce the hospital's patient transfer rate and increase its case mix index. This change will allow Phelps Health to treat a variety of neurological conditions so patients will not have to travel long distances for care.

For Phelps Health, the prioritization of teleNeurology services was an effort in community care, while the selection of SOC Telemed was about experience, reputation and the company's care quality credentials from The Joint Commission.

"We are proud to partner with SOC Telemed and their board-certified neurologists who can provide patient consultations for a variety of neurological conditions," says Keri Heavin, senior vice president and chief nursing officer at Phelps Health. "Using teleNeurology services provided by SOC Telemed, our patients can stay close to home for care and receive follow-up treatments with our Phelps Health neurologists."

Telemed IQ is in use today in more than 550 hospitals nationwide, enabling the right care, at the right time, when patients and communities need it most.

About Phelps Health Phelps Health is one of Missouri's leading regional referral centers, serving over 200,000 residents in south-central Missouri. Phelps Health is county-owned, non-tax supported and is overseen by a five-member elected board. Phelps Health employs more than 1,900 people, including 100-plus providers. Phelps Health, which includes a hospital licensed for 242 patient beds, serves a six-county area, with its main campus and several clinics located in Rolla, Missouri. Phelps Health also has clinics in Salem, St. James, Vienna and Waynesville, Missouri. Visit phelpshealth.org for more information.

About SOC Telemed SOC Telemed (SOC) is the largest national provider of telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC's technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry, and teleICU as well as enabling healthcare organizations to build sustainable telemedicine programs in any clinical specialty. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission's Gold Seal of Approval and has maintained that accreditation every year since inception. SOC Telemed is backed by Warburg Pincus and CRG. For more information, visit http://www.soctelemed.com.

Media Contact: Lauren Shankman Trevelino/Keller (404) 214.0722 Ext. 121 lshankman@trevelinokeller.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/soc-telemed-supports-phelps-health-with-round-the-clock-teleneurology-services-301072509.html

SOURCE SOC Telemed

Read this article:
SOC Telemed Supports Phelps Health with Round-The-Clock teleNeurology Services - Stockhouse

Neurologists Baffled By Length Of Time Some Patients Are Taking To Wake Up After Ventilators – Kaiser Health News

Posted on by

Normally a patient in a medically induced coma would wake up over the course of a day. Some COVID patients are taking nearly a week to wake up. In other scientific news on the virus: brain damage found in autopsies, the origin of the outbreak may be earlier than previously thought and the use of repeated tests is questioned.

The Washington Post:Some Covid-19 Patients Experience Prolonged Comas After Being Taken Off VentilatorsAfter five days on a ventilator because of covid-19, Susham Rita Singh seemed to have turned a corner. Around midnight on April 8, doctors at Houston Methodist Hospital turned off the sedative drip that had kept the previously healthy 65-year-old in a medically induced coma. The expectation is that you should start waking up after six hours, 12 hours or a day, said her daughter, Silky Singh Pahlajani, a neurologist in New York City. But it was six-and-a-half days before she started opening her eyes. I thought she had suffered a massive stroke. Her brain MRI was normal, which was great, but then the question became: Whats going on? (Hurley, 6/7)

CIDRAP:Autopsies Show Brain Damage In COVID-19 PatientsA study yesterday in The Lancet presents the clinical findings of autopsies conducted on six German patients (four men and two women, aged 58 to 82 years) who died from COVID-19 in April. All six had evidence of extensive brain pathologies at the time of death. Each patient had severe viral pneumonia caused by COVID-19 and required mechanical intubation or extracorporeal membrane oxygenation. (6/5)

ABC News:Satellite Data Suggests Coronavirus May Have Hit China Earlier: ResearchersDramatic spikes in auto traffic around major hospitals in Wuhan last fall suggest the novel coronavirus may have been present and spreading through central China long before the outbreak was first reported to the world, according to a new Harvard Medical School study. Using techniques similar to those employed by intelligence agencies, the research team behind the study analyzed commercial satellite imagery and "observed a dramatic increase in hospital traffic outside five major Wuhan hospitals beginning late summer and early fall 2019," according to Dr. John Brownstein, the Harvard Medical professor who led the research. (Folmer and Margolin, 6/8)

Stat:Experts Question Use Of Repeated Covid-19 Tests After A Patient RecoversThe very premature infant was born via cesarean section and quickly whisked away to the neonatal intensive care unit before his mother could even lay eyes on him. Over the next eight weeks, the only time she saw her baby was when the NICU staff sent photos, or when a nurse FaceTimed her while the baby was being bathed. The young mother, who gave birth at Montreals Sainte-Justine Hospital, tested positive for Covid-19 when her baby was born. For 55 days afterward, she repeatedly tested positive for the SARS-CoV-2 virus. Because she did, the hospital would not allow her to return after she was discharged meaning she could not hold or nurse her baby for the first two months of his life. (Branswell, 6/8)

See the article here:
Neurologists Baffled By Length Of Time Some Patients Are Taking To Wake Up After Ventilators - Kaiser Health News

Well-reputed Neurologist Dr. Habib Khan, MD, is Meritoriously Selected as a 2020 Patient Preferred Neurologist of the Year in the state of Arizona. -…

Posted on by

United States, Arizona, Casa Grande 06-09-2020 (PRDistribution.com) Dr. Habib Khan, MD, Medical Director at the Arizona Institute of Neurology & Polysomnography is meritoriously named a Patient Preferred Neurologist of the Year by the Patient Preferred Physicians & Practitioners Network for his achievements in Neurology and for achieving excellence in patient care.

With three decades in his field, Dr. Khan is a sought-after physician treating patients at the Arizona Institute of Neurology & Polysomnography in Casa Grande, AZ. His practice has also been selected for the 2020 Best of Casa Grande Award in the Doctor category by the Casa Grande Award Program. Along with his team of highly-skilled health care professionals, Dr. Khan has been rated five-stars by patients who praise his compassion, knowledge and care.

He is very thorough and knowledgeable. Yet, despite his obvious wealth of knowledge and experience, hes very humble, read a patient review. His calm, mild manner allows for a comfortable, no-stress experience. Every appointment he has encouraged self-care and truly listens to discern the underlying nature of the issue.

Dr. Khans patient philosophy includes providing each patient with the one-on-one time and attention they deserve for the best outcome, and quality of life changes. He has been listed among Arizonas top doctors and is a well-respected board certified neurologist and fellowship-trained sleep specialist. Patients seeking the best in neurological care come to Dr. Khan for his expertise in chronic headaches, peripheral neuropathy, epilepsy and seizures, dementia, and neuromuscular disorders such as myasthenia gravis. He also specializes in sleep apnea, insomnia, chronic pain issues, vertigo and other balance problems and is highly skilled at treating a wide variety of debilitating neurological conditions and sleep issues.

With passion, and a driven focus on patient care, Dr. Khans medical journey began with a Medical Degree from Dow Medical College in 1989. He then completed his residency program in neurology and internal medicine at the University of Medicine and Dentistry of New Jersey in Newark, and his fellowship in sleep medicine at the State University of New York at Stony Brook. Dr. Khan is also a diplomate of the American Board of Hospital Physicians and American College of Ethical Physicians.

To keep abreast of the latest developments in his field, Dr. Khan holds professional memberships with the American College of Physicians, American Medical Association, American Academy of Sleep Medicine, American Association of Neuromuscular and Electrodiagnostic Medicine, American Academy of Balance Medicine, and the American Institute of Ultrasound in Medicine.

Dr. Kahn displays great compassion and truly takes the time required to fully understand his patients medical issues and devise an appropriate treatment plan, read a patient review. I feel that he is the best at what he does and I would highly recommend him to others.

To make an appointment with Patient Preferred Neurologist of the Year, Dr. Habib Khan, MD please visit http://www.neurologycasagrande.net or call the office of Dr. Khan at [520] 423-2046.

Media Contacts:

Company Name: Patient Preferred Physicians & PractitionersFull Name: Lauren GoodPhone: Email Address: Send EmailWebsite: http://www.patientpreferredphysician.com

For the original news story, please visit https://prdistribution.com/news/well-reputed-neurologist-dr-habib-khan-md-is-meritoriously-selected-as-a-2020-patient-preferred-neurologist-of-the-year-in-the-state-of-arizona.html.

Powered by WPeMatico

See the original post here:
Well-reputed Neurologist Dr. Habib Khan, MD, is Meritoriously Selected as a 2020 Patient Preferred Neurologist of the Year in the state of Arizona. -...

PTSD Treatment: What Are the Most Effective Therapy Options? – Healthline

Posted on by

Recovering from trauma can often be difficult and slow going. What works for one person may not help someone else at all.

This is because people respond to trauma differently, and the effects of trauma can be complicated.

Trauma can cause physiological, neurological, and emotional effects some short-lived and others much longer lasting. When the effects of trauma dont go away or disrupt daily life, you may be experiencing post-traumatic stress disorder (PTSD).

Heres whats known about the treatment options for PTSD and what research tells us about the effectiveness of these treatments.

When you experience a traumatic event, your hypothalamic, pituitary, and adrenal systems release a surge of hormones to prepare you to fight, flee, or freeze.

In response, your heart rate speeds up, your breathing quickens, and your muscles tense. Your field of vision may narrow, your short-term memory may seem to go blank, and you might feel a sense of panic.

Even after the traumatic event ends, these symptoms can come and go for days or weeks.

You may have panic attacks or nightmares in response to similar sights, sounds, and smells even when theres no actual danger present.

In some cases, these symptoms persist for years. When symptoms continue for more than a month, you may be diagnosed with PTSD.

Around 10 to 20 percent of people who experience a trauma will develop PTSD symptoms afterward.

PTSD has been the focus of quite a lot of research. Several medications and therapeutic approaches have been shown effective in treatment.

Lets look at each of these treatment options in more detail:

Some forms of psychotherapy also known as talk therapy are effective treatments for PTSD.

Most of them are based on cognitive behavioral therapy (CBT), a kind of talk therapy that aims to identify and correct unhealthy and unrealistic thought patterns.

Cognitive processing therapy (CPT) is based on the idea that immediately following a trauma, you were probably not able to fully process what happened to you.

In trying to understand the event and how it affected you, you might later come to conclusions that arent healthy.

You might, for example, decide that its not safe to trust anyone, or you might believe that youre to blame for what happened.

CPT aims to identify those incorrect conclusions and restructure them in healthier ways. This kind of therapy usually takes place in around 12 sessions, during which you and your therapist work together to process what happened through talking or writing about the experience.

Like CPT, prolonged exposure therapy addresses the tendency to adopt unhealthy thinking patterns in the aftermath of a traumatic event.

For example, as a result of trauma, you may have developed a fear response thats out of proportion to the dangers you face.

To change your fear response, prolonged exposure therapy begins with some education about PTSD symptoms. Your therapist will equip you with skills to calm down and cope when you face something frightening.

Once youve learned self-calming techniques, you and your therapist will create a hierarchy of fears.

Youll start with things you find slightly scary and progress to more intense fears possibly those related to the trauma you experienced. You wont progress to the next level on your hierarchy until you and your therapist are satisfied you can handle each one.

Over several months of treatment, you and your therapist will work together to help you face your fears, allowing you to practice new coping skills.

Youll learn that your thoughts and memories related to the trauma arent actually dangerous and dont need to be avoided.

Many of the long-term effects of PTSD are neurological. For that reason, treatments that focus on the brain and nervous system have been found to be particularly effective at restoring function and reducing symptoms.

Eye movement desensitization and reprocessing (EMDR) is a therapy that uses repetitive eye movements to interrupt and re-pattern some of the trauma-related memories you have.

After talking about your history, you and your therapist will select a memory that you find particularly difficult.

While you bring the details of that memory to mind, your therapist will guide you through a series of side-to-side eye movements. As you learn to process the memory and related feelings it brings up, youll gradually be able to reframe that memory in a more positive light.

A 2018 review of research found that when provided by an experienced therapist, EMDR has the ability to reduce many symptoms of PTSD, including anxiety, depression, fatigue, and paranoid thought patterns.

Its a low-cost therapy, has few if any side effects, and is recommended by the World Health Organization (WHO) for treatment of PTSD.

Tapping is one element of a treatment approach called clinical emotional freedom technique (EFT).

Its similar to acupressure, a kind of massage treatment that uses physical pressure on certain sensitive points of the skin to relieve pain and muscle tension.

In a series of 4 to 10 sessions, a trained therapist can teach you how to tap certain rhythms on your hands, head, face, and collarbones while you actively reframe your memories of a traumatic event.

Tapping is often used along with cognitive and exposure therapies.

Studies have found that EFT therapies can reduce PTSD symptoms especially anxiety, depression, and pain.

EFT therapies may also decrease the amount of cortisol (a stress hormone) in your body.

Although you can eventually use tapping on your own, its important to work with a trained, licensed therapist as youre learning the techniques.

The short answer is a lot. A good starting place is to recognize the skills that enabled you to survive the trauma, even if those skills dont necessarily serve you well today.

You can also explore the many resources that have been developed to help trauma survivors recover from PTSD and regain their mental and physical health.

The National Center for PTSD provides a number of resources, including:

One of the most effective ways to process trauma is by writing.

Research has shown that writing about the traumatic event in several short sessions may help reduce symptoms of PTSD significantly.

In fact, some research has shown that combining writing with other therapies may help shorten your treatment time.

You dont necessarily have to write about the traumatic event on its own. Writing about your life as a whole, including traumatic events, may also help reduce PTSD symptoms.

An older study suggests that writing may also help lower blood pressure, improve anxiety and depression symptoms, and help with behavioral problems in children with PTSD.

Recent studies have shown that meditation and yoga are helpful complementary therapies for people with PTSD.

While yoga or meditation may not provide complete relief from symptoms, researchers recommend them as additions to therapy and medication.

Yoga may help you regulate your breathing, increase your awareness of your body, and respond to changing emotions.

Meditation may help you redirect your attention to the present moment, giving you a greater sense of control over intrusive memories.

To find a therapist who can help you with PTSD, consider the following strategies:

And finally, give yourself permission to change therapists.

The first therapist you visit might not turn out to be a good fit. Its OK to consider your initial visits as a kind of interview process to find the therapist thats right for you.

Most insurance plans offer some coverage for mental health services, although deductible amounts and copays will vary from policy to policy.

Original Medicare, Medicare Advantage plans, and Medicaid also provide mental health benefits.

If you dont have health insurance and youre looking for affordable PTSD treatment, try looking for a therapist who has a sliding-scale fee structure.

This search tool may be useful. The Open Path Psychotherapy Collective is another good option.

And if you need low-cost or free therapy, a community mental health center near you is an excellent starting point.

Trauma can cause physiological, neurological, and emotional effects. If the effects of trauma last longer than a month, or cause disruptions in your normal way of functioning, you may have PTSD.

The gold standard for treating PTSD symptoms is psychotherapy, particularly cognitive behavioral therapy, cognitive processing therapy, and prolonged exposure therapy.

EMDR and EFT have also shown promise in helping people recover from PTSD.

The effects of trauma are real and can have a powerful effect on the quality of your life, long after the event is over. But with time and the right treatment, there are ways to lessen the negative effects and restore your health and well-being.

See the article here:
PTSD Treatment: What Are the Most Effective Therapy Options? - Healthline

VCA Animal Referral & Emergency Center of Arizona has a neurology department that can treat a variety of conditions – Yahoo News

Posted on by

The Telegraph

Ursula von der Leyen on Monday pinned the blame for the vaccine fiasco that led Brussels to threaten a hard border on the island of Ireland on her trade commissioner Valdis Dombrovskis. The European Commission president threw her deputy, who leads DG Trade, under the bus amid rising anger from EU capitals at her go it alone tactics during last weeks battle with AstraZeneca. Jean-Claude Juncker, Mrs von der Leyen's predecessor, said he was "very much opposed" to her export restriction measures. In a speech in Stuttgart on Sunday, Mr Juncker also said of the EUs vaccine procurement: "It all went too slow, it all should have been done more transparently, even though that would have been difficult." This regulation falls under the responsibility of Mr Dombrovskis, said Eric Marmer, the European Commissions chief spokesman, referring to the former prime minister of Latvia, a Brussels veteran with a reputation for caution. In my country we have a saying, Only the Pope is infallible. Mistakes can happen along the way the important thing is that you recognise them early on, Mr Mamer said. Alexander Stubb, the former prime minister of Finland who campaigned to be appointed European Commission, president was scathing about Mrs Von der Leyen. He said "Number one rule of any leader: if your organisation screws up; never, ever blame your team publicly" Mrs von der Leyen was forced into a humiliating climbdown on Friday after announcing Brussels would trigger Article 16 of the Northern Ireland Protocol, to prevent AstraZeneca vaccines being smuggled into Britain from Northern Ireland. The move, which was announced without notifying Ireland or Britain, would have created a vaccine border after years of Brexit talks to avoid a hard border on the island. After the Irish prime minister called Mrs von der Leyen, the regulation, which could have facilitated a vaccine export ban to non-EU countries including Britain, was amended. Mr Mamer said that the regulation to create an export transparency mechanism, which including the Article 16 measure, was passed provisionally and at speed by the entire College of Commissioners on Friday. Asked by the Telegraph if this was Ms Van der Leyens worst week, he said: We believe that we are on the right track since the beginning of this pandemic in ensuring there is as cohesive and as effective a European response as possible. Mrs von der Leyens attempts to pass the buck cut no ice with EU diplomats, who suggested she had gone rogue, or German MPs in Berlin, who plan to summon Ursula von der Leyen for questioning. In a further blow to Mrs von der Leyen, the move was led by MPs from her own party, Angela Merkel's Christian Democrats (CDU). Mrs von der Leyen has refused calls for a public debate on the debacle in the European Parliament. Instead she will on Tuesday hold closed door meetings with MEPs with parties who approved her appointment. It is understood that Mrs von der Leyen took personal charge of the vaccine row and that DG Trades senior official is Sabine Weyand, whose objections to triggering Article 16 were reported to have been overruled. Ms Weyand is keenly aware of the political sensitivities around the Brexit divorce treatys Northern Ireland Protocol. She was Michel Barniers deputy Brexit negotiator and a key figure in the creation of the Irish border backstop.

More:
VCA Animal Referral & Emergency Center of Arizona has a neurology department that can treat a variety of conditions - Yahoo News

National Institute of Neurological Disorders and Stroke Awards $3.8 Million to Cleveland Clinic Researcher to Predict Dementia in Parkinson’s Disease…

Posted on by

Las Vegas: The National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NIH) has awarded a grant expected to total $3.8 million to Virendra Mishra, Ph.D., associate staff at Cleveland Clinic Lou Ruvo Center for Brain Health, to identify biomarkers or disease indicators to predict dementia in patients with Parkinsons disease.

Although dementia affects approximately 50-80% of those living with Parkinsons disease within 12 years of diagnosis, currently there are no means for predicting dementia in specific individuals, said Mishra. The possibility of identifying who will develop dementia with Parkinsons disease progression has several clinical benefits, including providing individuals with greater clarity on their future and helping clinicians better manage disease progression.

The five-year grant supports the project, Towards Generating a Multimodal and Multivarate Classification Model from Imaging and Non-Imaging Measures for Accurate Diagnosis and Monitoring of Dementia in Parkinsons Disease, which will use biomarkers spanning imaging, blood, cerebrospinal fluid and genetics to develop a predictive mathematical model to identify specific individuals with Parkinsons disease who may develop dementia as their disease progresses.

Utilizing sophisticated and pathologically relevant neuroimaging measures such as diffusion-weighted MRI and resting state functional MRI with non-imaging measures, including clinical data, demographics, genetics and cerebrospinal fluid, Mishra aims to:

Through this research, Mishra plans to develop a method that can be applied in clinical care with a greater-than-chance success rate to improve patient outcomes. In addition to clinical implications, identifying pathophysiology-based biomarkers for dementia in Parkinsons disease is critical for selecting appropriate individuals for participation in clinical trials of potential new disease-modifying therapies, and better understanding of the underlining pathophysiological processes.

Additionally, the novel imaging techniques developed for this research also can be applied in other neurodegenerative diseases such as Alzheimers disease to help advance the understanding of disease-specific neuroanatomical changes indicative of dementia.

This project is supported by NIH grant award R01NS117547.

For more information about ongoing research at Cleveland Clinic Lou Ruvo Center for Brain Health, visit ClevelandClinic.org/Nevada or call 702-701-7944.

More:
National Institute of Neurological Disorders and Stroke Awards $3.8 Million to Cleveland Clinic Researcher to Predict Dementia in Parkinson's Disease...

I have the rare Alice in Wonderland syndrome, here’s what it’s like – Insider – INSIDER

Posted on by

It would always happen late at night.

I would be lying in bed and gently winding down into sleep. My eyes would begin to feel peculiar, as though they were being squeezed. Suddenly, I would notice that the room around me had begun to appear as if I were looking at it down the wrong end of a telescope.

My bedroom furniture, my posters and ornaments, and the walls looked tiny, as though they were dollhouse-sized. At the same time, I felt huge, like I could reach out and touch the ceiling with my fingertips.

Everything I could see had a warped, fish-eye quality to it. If I turned on my bedroom light, the room would suddenly switch back to normal, but the only other "cure" for this odd phenomenon was falling asleep.

This happened to me frequently when I was a kid, most often when I was especially tired, ill, or stressed. I didn't have the words to explain what was happening to me at night, I only knew that it felt unusual and dream-like but I knew that I wasn't dreaming.

When I told my parents that sometimes at night "everything looked small" they took me to an optician, where I discovered that I needed glasses and my prescription meant that I had a problem with depth perception.

Problem solved, I thought. But the episodes kept happening.

Sometimes everything around me would look dollhouse-sized. zef art/Shutterstock

I wasn't frightened by these episodes where everything around me looked like a reflection in a fun-house mirror. I loved fairy tales, and what I was experiencing didn't seem odd in the context of magic wands, evil stepmothers, and kids being able to talk to animals.

As I grew older, the episodes became more infrequent and, eventually, I forgot they had ever happened. But recently one night I was lying in bed, feeling tired and stressed, and I felt the same familiar tightening around my temples.

Suddenly, the room around me shrunk to dollhouse proportions.

Amazed, I stretched out my seemingly giant hand and felt as though I could easily touch the far-off wall opposite my bed.

Later that same week, I happened to discover a New York Times article that finally had an explanation, a name, and a diagnosis for what was happening to me I had Alice in Wonderland syndrome.

Discovered in 1955 by British psychiatrist John Todd, episodes of this rare curiosity, also known as Todd's syndrome, tend to involve macropsia (objects appearing larger than they are), teleopsia (objects appearing further away than they are), and micropsia (objects appearing smaller than they are).

Some people who experience this perceive their own body parts as being larger or smaller than in reality, and the whole episode can be accompanied by a sense of derealization (feeling like things around you aren't real) and depersonalization (feeling detached from your own body or mind).

It's sort of similar to what Alice experienced when she ate the mushroom in Lewis Carroll's famous book "Alice's Adventures in Wonderland" and altered the size of her body hence the name of the syndrome.

The syndrome has been linked to migraines, epilepsy, strokes, head trauma, infections, drugs, and stress but it's not known to be dangerous.

It's also not yet clear what causes the illusions and distortions, although it's not believed to be a hallucination or an eyesight problem.

Alice and the mushroom pieces in "Alice in Wonderland" (1951). Disney

Some who have studied this under-researched syndrome believe it's caused by changes in the portion of the brain that processes how we see our environment, possibly because of electrical activity which causes abnormal blood flow to that area.

Some doctors also believe it to be a type of migraine aura, which are sensory disturbances that can sometimes alter one's vision just before a migraine.

Dr. Grant Liu, a pediatric neuro-ophthalmologist at the Children's Hospital of Philadelphia, said he's seen a lot of patients with "odd complaints" over the years.

"Kids complain of seeing things that are too small, too large, too close, and too far away," he told Insider.

A few years ago, he conducted a study into Alice in Wonderland syndrome where he examined and spoke to 48 patients who experienced symptoms between 1993 and 2013.

He was able to link 33% of cases of the syndrome to exposure to infections (such as the flu), 6% to head trauma, and 6% to migraines. But in 52% of the cases, no cause was found.

His research also found that although the syndrome typically affects young children, it continued until later in life for about a third of patients he studied.

Miniature Alice and the Mad Hatter in "Alice in Wonderland" (2010). Walt Disney Studios

ButDr. Liu said he was most fascinated by the familial link he's seen with the syndrome, which makes him think that it could be more common than people think.

"For the study, we called families to follow up five to 15 years after diagnosing their children with Alice in Wonderland syndrome," he told Insider. "During those phone calls, lots of parents admitted that they too had experienced symptoms as children but when they were in the exam room, they were too embarrassed to admit it."

Although Dr. Liu said people experiencing Alice in Wonderland syndrome should see a specialist, as it can be a manifestation of a seizure or a migraine, he was quick to assure me that "there's no treatment necessary, it's really just reassurance."

People are less lonely when they embrace uncertainty and feel empathy, a study found

Disney once owned a town in Florida called Celebration, but the reality isn't very magical

How getting breast-reduction surgery helped me lose 50 pounds and changed my life

See the article here:
I have the rare Alice in Wonderland syndrome, here's what it's like - Insider - INSIDER

Monday Pharmaceutical Mystery: What Medication May Be Causing Neurological Symptoms? – Pharmacy Times

Posted on by

Monday Pharmaceutical Mystery: What Medication May Be Causing Neurological Symptoms?

She has been in the hospital for 5 days and during that time the doctors did all the expensive tests looking for blood clots, ischemia,inflammation, infection, and malignancies in the brain andnervoussystem. But they find nothing. The doctor says he is at a loss to what is causing JKs symptoms.

As the pharmacist for the team, you review JKs medications, and the dosages according to her weight of 86 kg and renal function of eCrCl of 45 ml/min.

Mystery: Which is the medication dose you want to lower and why?

Solution: Gabapentin. JK had a decline in renal function, as verified by changes in SrCr, and that caused gabapentin to accumulate to toxic levels. JK will need a new lower dose to stay symptom-free.Renal disease for gabapentin are as follows: eCrCl 30-59ml/min 700mg bid, eCrCl 15-29 ml/min 700mg qd, eCrCl <15 ml/min 300mg/day.1

Drug levels for gabapentin can easily accumulate and reach toxic levels when renal function declines or when the recommended dosage is exceeded. I believe this is an under recognized problem that can be easily addressed by pharmacists.2

REFERENCES

Read more:
Monday Pharmaceutical Mystery: What Medication May Be Causing Neurological Symptoms? - Pharmacy Times

Interventional Neurology Device Market Outlook, Recent Trends and Growth Forecast 2020-2025 – The Research Process

Posted on by

Latest update on Interventional Neurology Device Market Analysis report published with an extensive market research, Interventional Neurology Device market growth analysis and Projection by 2025. this report is highly predictive as it holds the over all market analysis of topmost companies into the Interventional Neurology Device industry. With the classified Interventional Neurology Device market research based on various growing regions this report provide leading players portfolio along with sales, growth, market share and so on.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/300

A Interventional Neurology Device market analysis report covers historical data of recent five years along with a forecast from to 2025 based on revenue. This report includes drivers and restraints of the global Interventional Neurology Device market along with the impact they have on the demand over the forecast period. Also, the report provides company Interventional Neurology Device market share analysis to give a broader overview of the key players in the market.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/300

The report evaluates several factors determining the Interventional Neurology Device market expansion as well as the volume of the whole Market. The report states the aggressive vendor scenery of the market together with the profiles of some of the leading Interventional Neurology Device market players.

Some of the Major Interventional Neurology Device Market Players Are:

The report provides data taking into attention the latest advancements in the global Interventional Neurology Device Market while appraising the impact in the Interventional Neurology Device market of the most important players in the near future.

Interventional Neurology Device Market Outlook by Applications:

Treatment of Cerebral Aneurysms, Treatment of Cerebral Vasospasm and Vertebroplasty

Interventional Neurology Device Market Statistics by Types:

Embolization & coiling and Neurothrombectomy Devices

Objective of Studies of Interventional Neurology Device Market:

The Interventional Neurology Device research report provides answers to the following key questions:

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/300

View post:
Interventional Neurology Device Market Outlook, Recent Trends and Growth Forecast 2020-2025 - The Research Process

Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings – GlobeNewswire

Posted on by

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it will highlight its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing technology (ADAR editing) and its neurology programs in Huntingtons disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at upcoming conferences, including the TIDES: Oligonucleotide and Peptide Therapeutics 2020 meeting and the 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place on September 15-18, 2020 and September 27-30, 2020, respectively.

At TIDES and OTS, Wave will share how it is developing ADAR editing as a potentially best-in-class RNA editing approach with applicability across multiple genetic diseases. Notably, one of Waves presentations at TIDES will include the companys first ADAR editing data in ex vivo retina samples from non-human primates (NHPs). These data add to the growing body of in vitro and in vivo data the company has generated, which include editing in the liver of NHPs and the central nervous system in a humanized mouse model, in support of ADAR editing as an emerging platform capability at Wave.

Another presentation at TIDES will highlight Waves neurology pipeline, including its C9orf72 variant-selective silencing program for ALS and FTD, as well as its SNP3 program for HD, both of which are expected to initiate clinical development with the submission of clinical trial applications in the fourth quarter of 2020.

Details of Data Presentations

TIDES: Oligonucleotide and Peptide Therapeutics 2020 meeting

16th Annual Meeting of the Oligonucleotide Therapeutics Society

About PRISMPRISM is Wave Life Sciences proprietary discovery and drug development platform that enables genetically defined diseases to be targeted with stereopure oligonucleotides across multiple therapeutic modalities, including silencing, splicing and editing. PRISM combines the companys unique ability to construct stereopure oligonucleotides with a deep understanding of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. By exploring these interactions through iterative analysis ofin vitroandin vivooutcomes and machine learning-driven predictive modeling, the company continues to define design principles that are deployed across programs to rapidly develop and manufacture clinical candidates that meet pre-defined product profiles.

About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the companys proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit http://www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the development of ADAR editing as a potentially best-in-class RNA editing approach and emerging platform capability at Wave; the potential for Waves preclinical data, including data from and its neurology programs in Huntingtons disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD); and the expected timing for the initiation of clinical development for Waves C9orf72 variant-selective silencing program for ALS and FTD, as well as its SNP3 program for HD. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled Risk Factors in Waves most recent Annual Report on Form 10-K filed with theSecurities and Exchange Commission(SEC), as amended, and in other filings Wave makes with theSECfrom time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances

Investor Contacts:Kate Rausch617-949-4827krausch@wavelifesci.com

Graham Morrell781-686-9600gmorrell@wavelifesci.com

Media Contact:Alicia Suter617-949-4817asuter@wavelifesci.com

Excerpt from:
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings - GlobeNewswire

Beebe warning parents of Acute Flaccid Myelitis, they say don’t ignore symptoms and go to the doctors – 47abc – WMDT

Posted on by

DELAWARE Beebe Healthcare is warning parents to monitor symptoms in children for a polio-like virus.

The CDC recently sent out an alert on Acute Flaccid Myelitis saying they expect a higher number of cases this year.

This rare polio-like neurological condition typically impacts kids.

A doctor at Beebe said they are not sure why cases are supposed to be higher, but since the virus was first recognized in 2014, there has been an increase in the number of cases in even numbered years; and because of this they are stressing that parents keep an eye out for symptoms that include respiratory problems, fever, muscle weakness, and trouble speaking or swallowing.

I think the bigger things is dont ignore symptoms because of fear of going to the doctor, I think we are hopeful that because everybody has been social distancing and everybody has been masking the spike may be still might not happen, Nicole Ryan, a pediatric neurologist, said.

Doctors told us the virus can be spread from person to person, so parents should be enforcing the same type of precautions that they are taking for the COVID-19 pandemic.

View original post here:
Beebe warning parents of Acute Flaccid Myelitis, they say don't ignore symptoms and go to the doctors - 47abc - WMDT

Neurologic Disorders Therapeutics Market 2020 | Know The Latest Covid19 Impact Analysis And Strategies Of Key Players: Biogen Inc., F. Hoffmann-La…

Posted on by

Neurologic Disorders Therapeutics Market Research Report provides a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2026. A Neurologic Disorders Therapeutics market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

Impact Analysis of COVID-19: The complete version of the Neurologic Disorders Therapeutics Market Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, regional and technological parameters.

Covid-19 Impact analysison Neurologic Disorders Therapeutics Market, get on mail athttps://www.worldwidemarketreports.com/sample/355636

This Neurologic Disorders Therapeutics market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc. are some of the major organizations dominating the global market.(Other Players Can be Added per Request)

Key players in the Neurologic Disorders Therapeutics market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Neurologic Disorders Therapeutics market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

Get the Exclusive sample PDF of Neurologic Disorders Therapeutics Market with few listed Key Players 2020-https://www.worldwidemarketreports.com/sample/355636

The report also makes some important suggestions for the new Neurologic Disorders Therapeutics market project before evaluating its feasibility. Overall, this report covers Neurologic Disorders Therapeutics market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

The Report Covers Segments Analysis also-

On the basis of Types, Neurologic Disorders Therapeutics Market is segmented into- Central Nervous System (CNS), Peripheral Nervous System (PNS)

On the Basis of Application, the Neurologic Disorders Therapeutics Market is segmented as- Paralysis, Muscle Weakness, Poor Coordination, Loss of Sensation, Seizures, Confusion, Pain and Altered Levels of Consciousness

Complete knowledge of the Neurologic Disorders Therapeutics market is based on the latest industry news, opportunities and trends in the expected region. The Neurologic Disorders Therapeutics market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Neurologic Disorders Therapeutics Market Report:

Customization or Quriy on the Report, click athttps://www.worldwidemarketreports.com/quiry/355636

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

The rest is here:
Neurologic Disorders Therapeutics Market 2020 | Know The Latest Covid19 Impact Analysis And Strategies Of Key Players: Biogen Inc., F. Hoffmann-La...

Global Neurology EMR Software Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | NueMD, Greenway Health, AdvancedMD,…

Posted on by

The report contains a thorough summary of Neurology EMR Software Market that includes several well-known organizations, key market players who are leading in terms of sales, variable market change, revenue, end-user demands, conformity through trustworthy services, restricted elements, products and other processes. Technical advancements, surplus capacity in developing markets, market bifurcation, globalization, regulations and environmental guidelines, production and packaging are some trends that are explained in the market report.

The Global Neurology EMR Software Market will arrive at critical CAGR during estimate period 2020-2027. Furthermore, this report presents showcase rivalry circumstance among the sellers and friends profile, in addition, advertise value examination and worth chain highlights are shrouded in this report.

Following Top Key Players are profiled with global positioning:

NueMDGreenway HealthAdvancedMDAthenahealthPrognoCIS by BizmaticsKareoAprima EHR SoftwareAzalea HealtheClinicalWorksCureMDChartLogic EHR SuiteDocLinks

Get Free Sample PDF (including full TOC, Tables and Figures) of Neurology EMR Software Market @ https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/#sample

The Neurology EMR Software market research report investigates the market as far as income and developing business sector patterns and drivers and incorporates a cutting-edge examination and estimates for different market portions, significant players and every single land area till 2027 and the worldwide pandemic of COVID-19 calls for rethinking of business methodologies. This Neurology EMR Software market report incorporates the effect investigation vital for the equivalent.

Global Neurology EMR Software market report gives a select inclusion which has been accommodated market drivers and challenges & opportunities for a nation level market in the particular provincial sections. The report contains a serious examination of the key players working in the market and covers inside and out information identified with the serious scene of the market and the ongoing methodologies and items that will help or influence the market in the coming years.

Global Neurology EMR Software market report client gets detailed and verified data about the business. Likewise, this report covers the top to bottom factual investigation and the market elements and requests which give an entire situation of the business. The report gives the distinctive business challenges which are affecting business sector development a positive and negative way.

Global Neurology EMR Software Market Segmentation By Type:

Type IType II

Global Neurology EMR Software Market Segmentation By Applications:

Medical FacilitiesResearch InstitutesOthers

Global Neurology EMR Software Market Segmentation By Regions:

Place Inquiry for Buying or Customization of Report: https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/#inquiry

The report also provides the current industry value according to the demand. This report consists the all over the information regarding the Neurology EMR Software market. By using this report user get a clear perspective on the Neurology EMR Software market conditions, trends, and coming period outlook for various segments.

By referring this report user understanding the overall behavior of the consumers in the market place and reasons for those behavioral trends. Also by using the focus groups, surveys, and tracking sales history methods a user can analyze the psychological, personal, and social consumer behavior. As a result, users can plan their strategies and getting the most important sub segments of the market which they are targeting. So, the report helps businesses to get segments according to their consumer-based information.

The Neurology EMR Software market report offers the current state of the market around the world. The report began with the market outline and key components of the Neurology EMR Software market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Neurology EMR Software market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Neurology EMR Software business and market elements.

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overviewChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses.Chapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Neurology EMR Software Research Findings and Conclusion, Appendix, methodology and data source.

Continued here:
Global Neurology EMR Software Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | NueMD, Greenway Health, AdvancedMD,...

Coronavirus: What does Covid-19 do to the brain? – BBC News

Posted on by

Image caption Consultant neurologist Arvind Chandratheva points out brain damage on a scan

Stroke, delirium, anxiety, confusion, fatigue - the list goes on. If you think Covid-19 is just a respiratory disease, think again.

As each week passes, it is becoming increasingly clear that coronavirus can trigger a huge range of neurological problems.

Several people who've contacted me after comparatively mild illness have spoken of the lingering cognitive impact of the disease - problems with their memory, tiredness, staying focused.

But it's at the more severe end that there is most concern.

Chatting to Paul Mylrea, it's hard to imagine that he had two massive strokes, both caused by coronavirus infection.

The 64-year-old, who is director of communications at Cambridge University, is eloquent and, despite some lingering weakness on his right side, able-bodied.

He has made one of the most remarkable recoveries ever seen by doctors at the National Hospital for Neurology and Neurosurgery (NHNN) in London.

His first stroke happened while he was in intensive care at University College Hospital. Potentially deadly blood clots were also found in his lungs and legs, so he was put on powerful blood-thinning (anticoagulant) drugs.

A couple of days later he suffered a second, even bigger stroke and was immediately transferred to the NHNN in Queen Square.

Consultant neurologist Dr Arvind Chandratheva was just leaving hospital when the ambulance arrived.

"Paul had a blank expression on his face," he says. "He could only see on one side and he couldn't figure out how to use his phone or remember his passcode.

"I immediately thought that the blood thinners had caused a bleed in the brain, but what we saw was so strange and different."

Paul had suffered another acute stroke due to a clot, depriving vital areas of the brain of blood supply.

Tests showed that he had astonishingly high levels of a marker for the amount of clotting in the blood known as D-dimer.

Normally these are less than 300, and in stroke patients can rise to 1,000. Paul Mylrea's levels were over 80,000.

"I've never seen that level of clotting before - something about his body's response to the infection had caused his blood to become incredibly sticky," says Dr Chandratheva.

During lockdown there was a fall in the number of emergency stroke admissions. But in the space of two weeks, neurologists at the NHNN treated six Covid patients who'd had major strokes. These were not linked to the usual risk factors for stroke such as high blood pressure or diabetes. In each case they saw very high levels of clotting.

Part of the trigger for the strokes was a massive overreaction by the immune system which causes inflammation in the body and brain.

Dr Chandratheva projected Paul's brain images on a wall, highlighting the large areas of damage, shown as white blurs, affecting his vision, memory, coordination, and speech.

The stroke was so big that doctors thought it likely he would not survive, or be left hugely disabled.

"After my second stroke, my wife and daughters thought that was it, they would never see me again," Paul says. "The doctors told them there was not much they could do except wait. Then I somehow survived and have been getting progressively stronger."

One of the first encouraging signs was Paul's ability with languages - he speaks six - and he would switch from English to Portuguese to speak to one of his nurses.

"Unusually he learned several of his languages as an adult, and this will have created different wiring connections in the brain which have survived his stroke," says Dr Chandratheva.

Paul says he cannot read as fast as he used to, and is sometimes forgetful, but that's hardly surprising given the areas of damage in his brain.

His physical recovery has also been impressive, which doctors attribute to his previous very high level of fitness.

"I used to cycle for an hour a day, do a couple of gym sessions a week and swim in the river. My cycling and diving days are over, but I hope to get back to swimming," Paul says.

A study in the Lancet Psychiatry found brain complications in 125 seriously ill coronavirus patients in UK hospitals. Nearly half had suffered a stroke due to a blood clot while others had brain inflammation, psychosis, or dementia-like symptoms.

One of the report authors, Prof Tom Solomon of the University of Liverpool, told me, "It's clear now that this virus does cause problems in the brain whereas initially we thought it was all about the lungs. Part of it is due to lack of oxygen to the brain. But there appear to be many other factors, such as problems with blood clotting and a hyper-inflammatory response of the immune system. We should also ask whether the virus itself is infecting the brain."

Media playback is unsupported on your device

In Canada, neuroscientist Prof Adrian Owen has launched a global online study of how the virus affects cognition. Owen said: "We already know that ICU survivors are vulnerable to cognitive impairment. So as the number of recovered Covid-19 patients continues to climb, it's becoming increasingly apparent that getting sent home from the ICU is not the end for these people. It's just the beginning of their recovery."

"Sars and Mers, which are both caused by coronaviruses, were associated with some neurological disease, but we've never seen anything like this before," Dr Michael Zandi, consultant neurologist at the NHNN, told me. "The closest comparison is the 1918 flu pandemic. We saw then there was a lot of brain disease and problems that emerged over the next 10-20 years."

As the BBC's medical correspondent, since 2004 I have reported on global disease threats such as bird flu, swine flu, Sars and Mers - both coronaviruses - and Ebola. I've been waiting much of my career for a global pandemic, and yet when Covid-19 came along, the world was not as ready as it could have been. Sadly, we may have to live with coronavirus indefinitely. Here, I will be reflecting on that new reality.

A mysterious neurological syndrome known as encephalitis lethargica appeared around the end of World War One and went on to affect more than a million people worldwide. There is limited evidence of its causes, and whether the trigger was influenza or a post-infectious autoimmune disorder.

As well as a sleepiness coma, some patients had movement disorders that looked like Parkinson's disease, which affected them for the rest of their lives.

In his book Awakenings, the neurologist Oliver Sacks told the story of a group of patients who'd been frozen in sleep for decades, and how he used the drug L-Dopa to temporarily free them from their locked-in state.

We should be careful before reading too much into comparisons between Covid-19 and the 1918 Spanish flu pandemic. But with so many Covid patients having neurological symptoms, it will be important to look at the long-term effects on the brain.

Media playback is unsupported on your device

Follow @BBCFergusWalsh on Twitter

Originally posted here:
Coronavirus: What does Covid-19 do to the brain? - BBC News